• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Castle Biosciences Inc.

    8/15/25 5:19:20 PM ET
    $CSTL
    Medical Specialities
    Health Care
    Get the next $CSTL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001239501
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Castle Biosciences, Inc.
    SEC File Number
    001-38984
    Address of Issuer
    505 S. Friendswood Drive
    Suite 401
    Friendswood
    TEXAS
    77546
    Phone
    1-866-788-9007
    Name of Person for Whose Account the Securities are To Be Sold
    Derek Maetzold
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Goldman Sachs & Co. LLC
    200 West Street
    New York � NY � 10282
    401780701.532900828108/15/2025
    NASD


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/09/2024Acquired as compensation -- Performance AwardsIssuerCheckbox not checked401708/09/2024Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    The Maetzold Descendants 2020 Trust dtd 12/4/2020
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/20258068163804.6
    The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/202566013399.98
    The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/202566013399.98
    Derek Maetzold
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/20254944100378.03
    Derek Maetzold 2020 Irrevocable Trust dtd 12/04/2020
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/20256924140577.97
    The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/202566013399.98
    The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common06/27/202566013399.98
    Derek Maetzold
    505 S. Friendswood Drive
    Suite 401
    Friendswood � TX � 77546
    Common08/13/202543019836452.83

    144: Remarks and Signature

    Remarks
    The sales of shares set forth herein are made in connection with a selling plan dated 5/8/2025 that is intended to comply with Rule 10b5-1(c).
    Date of Notice
    08/15/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/08/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldman Sachs & Co. LLC on behalf of Derek Maetzold

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CSTL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CSTL

    DatePrice TargetRatingAnalyst
    12/14/2023$25.00Buy
    Guggenheim
    1/5/2023$54.00Sector Outperform
    Scotiabank
    1/7/2022$59.00Overweight
    Stephens & Co.
    11/9/2021$85.00 → $75.00Outperform
    SVB Leerink
    7/14/2021$80.00 → $85.00Outperform
    SVB Leerink
    More analyst ratings

    $CSTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Castle Biosciences Reports Second Quarter 2025 Results

    Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th

    8/4/25 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

    FRIENDSWOOD, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast. About Castle BiosciencesCastle Biosciences (NASDAQ:CSTL) is a leading di

    7/29/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

    FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community. "Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient o

    7/25/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    SEC Filings

    View All

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    8/15/25 5:19:20 PM ET
    $CSTL
    Medical Specialities
    Health Care

    SEC Form 144 filed by Castle Biosciences Inc.

    144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    8/13/25 5:30:12 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - CASTLE BIOSCIENCES INC (0001447362) (Filer)

    8/8/25 4:04:57 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Exec. Officer Maetzold Derek J sold $26,834 worth of shares (1,339 units at $20.04), decreasing direct ownership by 2% to 68,344 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/19/25 4:04:43 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J sold $839,043 worth of shares (43,019 units at $19.50), decreasing direct ownership by 38% to 69,683 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/15/25 4:14:28 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Pres. & Chief Exec. Officer Maetzold Derek J covered exercise/tax liability with 23,972 shares and converted options into 66,991 shares, increasing direct ownership by 62% to 112,702 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    8/12/25 4:32:21 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Castle Biosciences with a new price target

    Guggenheim initiated coverage of Castle Biosciences with a rating of Buy and set a new price target of $25.00

    12/14/23 6:54:55 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Castle Biosciences with a new price target

    Scotiabank initiated coverage of Castle Biosciences with a rating of Sector Outperform and set a new price target of $54.00

    1/5/23 7:53:37 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Stephens & Co. initiated coverage on Castle Biosciences with a new price target

    Stephens & Co. initiated coverage of Castle Biosciences with a rating of Overweight and set a new price target of $59.00

    1/7/22 5:42:05 AM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

    The Company is proud to collaborate on a number of additional initiatives during the month of May Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month. The first such event is a ribbon cutting to honor the City of Friendswood's designation as a Sun Safe Leadership Model City — the first in Texas — by IMPACT Melanoma. The ribbon cutting will take place at Stevenson Park in Friendswood, Texas, on Friday, May 3, 2024, at 10:00 a.m. Central time. "Skin cancer is the most common cancer in the Unit

    4/30/24 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors

    SAN DIEGO, May 26, 2021  /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience. Mr. Maetzold is the Founder and CEO of publicly listed Castle Biosciences (NASDAQ:CSTL). Previously he held leadership roles at Encysive Pharmaceuticals, Amylin Pharmaceuticals, Sandoz and Schering-Plough. Castle Biosciences has gained Medicare reimbursement coverage and has had a successful

    5/26/21 12:42:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/13/24 6:44:33 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    7/8/24 4:32:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    $CSTL
    Financials

    Live finance-specific insights

    View All

    Castle Biosciences Reports Second Quarter 2025 Results

    Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2025."Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect th

    8/4/25 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

    FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/164444215, or via the webcast link on the Investor Relations page of the Company's website: https://ir.cast

    7/14/25 7:00:00 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Castle Biosciences Reports First Quarter 2025 Results

    Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. "We are pleased with the exceptional start to the year, marked by continued growth in test report volum

    5/5/25 4:06:00 PM ET
    $CSTL
    Medical Specialities
    Health Care